The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.
The George Institute China at Peking University Health Sciences Center, Beijing, China.
Cerebrovasc Dis. 2023;52(3):251-254. doi: 10.1159/000526384. Epub 2022 Sep 5.
The third INTEnsive care bundle with blood pressure Reduction in Acute Cerebral hemorrhage Trial (INTERACT3) is an international, multicenter, stepped-wedge (4 phases/3 steps) cluster randomized trial involving 110 hospitals in mainly low- and middle-income countries during 2017-2022. The aim is to determine the effectiveness of a goal-directed care bundle of intensive blood pressure (BP) lowering, glycemic control, antipyrexia, and anticoagulation reversal treatment versus usual standard of care, in patients with acute intracerebral hemorrhage (ICH). After a "usual care" period, hospitals were randomly allocated to implementing care-bundle protocols for control targets (systolic BP <140 mm Hg; glucose 6.1-7.8/7.8-10.0 mmol/L according to diabetes mellitus status; temperature ≤37.5°C; normalization of anticoagulation). A sample size of 8,360 patients (mean 19 per phase per site) provides 90% power (α = 0.05) for a 5.6% absolute improvement in the primary outcome of scores on the modified Rankin scale at 6 months, analyzed by ordinal logistic regression. A detailed statistical analysis plan (SAP) was developed to prespecify the method of analysis for all outcomes and key variables collected in the trial. The primary analysis will use ordinal logistic regression adjusted for the stepped-wedge design. The SAP also includes planned sensitivity analyses, including covariate adjustments, missing data imputations, and subgroup analysis. This SAP allows transparent, verifiable, and prespecified analyses in consideration of the challenges in conducting the study during the COVID pandemic. It also avoids analysis bias arising from prior knowledge of the findings in determining the benefits and harms of a care bundle in acute ICH.
《急性脑出血强化降压与血压控制试验 3 期研究》(INTERACT3)是一项国际性、多中心、梯次(4 个阶段/3 个步骤)集群随机试验,于 2017 年至 2022 年在主要来自中低收入国家的 110 家医院开展。本研究旨在确定强化降压(BP)、血糖控制、退热和抗凝逆转治疗目标导向护理包与急性脑出血(ICH)患者常规护理相比的有效性。在“常规护理”阶段后,医院被随机分配实施控制目标的护理包方案(收缩压<140mmHg;根据糖尿病状态,血糖 6.1-7.8/7.8-10.0mmol/L;体温≤37.5°C;抗凝正常化)。每个阶段每个地点 19 例患者的样本量(8360 例患者)提供了 90%的功效(α=0.05),用于分析 6 个月时改良 Rankin 量表评分的主要结局的绝对改善率为 5.6%,采用有序逻辑回归分析。制定了详细的统计分析计划(SAP),以预先规定试验中所有结局和关键变量的分析方法。主要分析将使用调整梯次设计的有序逻辑回归进行。SAP 还包括计划的敏感性分析,包括协变量调整、缺失数据插补和亚组分析。该 SAP 考虑到在 COVID 大流行期间开展研究的挑战,允许进行透明、可验证和预设分析。它还避免了由于事先了解急性 ICH 护理包的益处和危害而产生的分析偏差。